Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iterum Therapeutics Plc

1.08
+0.03002.86%
Post-market: 1.05-0.0300-2.78%18:23 EDT
Volume:215.60K
Turnover:234.34K
Market Cap:37.35M
PE:-0.86
High:1.10
Open:1.05
Low:1.05
Close:1.05
Loading ...

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

GlobeNewswire
·
14 Apr

Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ...

GuruFocus.com
·
08 Feb

Iterum Therapeutics Faces Commercialization Challenges for ORLYNVAH™ Despite FDA Approval

TIPRANKS
·
08 Feb

Q4 2024 Iterum Therapeutics PLC Earnings Call

Thomson Reuters StreetEvents
·
08 Feb

BRIEF-Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million

Reuters
·
08 Feb

Iterum Therapeutics files $150M mixed securities shelf

TIPRANKS
·
08 Feb

Iterum Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
07 Feb

Iterum Therapeutics Q4 2024 Adj EPS $(0.12) Beats $(0.21) Estimate

Benzinga
·
07 Feb

Iterum Therapeutics Q4 Adjusted Net Income USD -3.14 Million

THOMSON REUTERS
·
07 Feb

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
07 Feb

Iterum Therapeutics PLC expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
05 Feb

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

GlobeNewswire
·
31 Jan

Iterum Therapeutics Plc Files for Offering of up to $25 Mln of Ordinary Shares - SEC Filing

THOMSON REUTERS
·
10 Dec 2024

Iterum Therapeutics Shares Rise After Regaining Compliance With Nasdaq's Listing Rules

MT Newswires Live
·
22 Nov 2024

Iterum Therapeutics regains full Nasdaq compliance

TIPRANKS
·
21 Nov 2024

Iterum Therapeutics Regains Full Nasdaq Compliance

THOMSON REUTERS
·
21 Nov 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...

GuruFocus.com
·
15 Nov 2024

Iterum Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Iterum Therapeutics Q3 2024 Adj. EPS $(0.24) Misses $(0.20) Estimate. Cash And Equivalents Of $14.5M

Benzinga
·
14 Nov 2024

Iterum Therapeutics Q3 Adjusted Net Income USD -4.837 Million

THOMSON REUTERS
·
14 Nov 2024